Dette er, fordi patienter, der fik én eller to behandlinger med TYSABRI og derefter ingen behandling i en periode på tre måneder eller mere, havde større sandsynlighed for at få en allergisk reaktion, når behandlingen blev genoptaget.
This is because patients who received one or two doses of TYSABRI and then had a gap in treatment of three months or more, were more likely to have an allergic reaction when resuming treatment.